

Announcement No. 4/2011 To NASDAQ OMX Copenhagen Exiqon A/S Skelstedet 16 2950 Vedbæk Denmark

Phone: +45 4566 0888 Fax: +45 4566 1888 exiqon@exiqon.com www.exiqon.com CVR/Tax ld: 18 98 44 31

Major shareholder announcement

Exiqon A/S (NASDAQ OMX Copenhagen: "EXQ") today announced that Danske Bank has informed the company that Danske Bank, including Danica Pension Livsforsikring and Danske Fund FPC, owns 2,974,983 shares of DKK 1 each corresponding to a nominal value of DKK 2,974,983 in Exiqon A/S directly. Danske Bank has informed the company that it can indirectly influence additional voting rights for 898,083 shares in Exiqon A/S. The rights of Danske Bank correspond to ownership of 8.92% of the share capital and voting rights of 11.62% in Exiqon A/S.

Additional information

Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101) Hans Henrik Chrois Christensen, CFO, tel. +45 4566 0888 (cell: +45 4090 2131)

About Exigon

Exiqon's products are based on the proprietary LNA[™] technology. This technology offers unique advantages for detection of microRNA biomarkers for life science researchers, drug developers and cancer treating physicians working towards personalizing medicine. Exiqon operates in two business areas: Exiqon Life Sciences has established a position for itself as one of the market's leading providers of microRNA research products for microRNA analysis in cells. Our research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Life Sciences is also collaborating with pharmaceutical companies in their effort to develop new medicines based on microRNA as biological markers. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions. Exiqon is listed on the NASDAQ OMX in Copenhagen. For more information about us, please visit <u>www.exiqon.com</u>.

